COX-2: A target for colon cancer prevention

Lawrence J. Marnett, Raymond N. DuBois

Research output: Contribution to journalArticle

273 Citations (Scopus)

Abstract

Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention.

Original languageEnglish (US)
Pages (from-to)55-80
Number of pages26
JournalAnnual Review of Pharmacology and Toxicology
Volume42
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Colonic Neoplasms
Drug Approval
Biochemistry
Health care
Pharmaceutical Preparations
Health Care Costs
Life Style
Neoplasms
Genes
Genome
Pharmacology
Enzymes
Research
Costs

Keywords

  • Cancer
  • Cyclooxygenase
  • NSAIDs
  • Prevention
  • Prostaglandins

ASJC Scopus subject areas

  • Pharmacology
  • Toxicology

Cite this

COX-2 : A target for colon cancer prevention. / Marnett, Lawrence J.; DuBois, Raymond N.

In: Annual Review of Pharmacology and Toxicology, Vol. 42, 2002, p. 55-80.

Research output: Contribution to journalArticle

Marnett, Lawrence J. ; DuBois, Raymond N. / COX-2 : A target for colon cancer prevention. In: Annual Review of Pharmacology and Toxicology. 2002 ; Vol. 42. pp. 55-80.
@article{f16fffb31e2d44e8a04d589f8229bb4f,
title = "COX-2: A target for colon cancer prevention",
abstract = "Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention.",
keywords = "Cancer, Cyclooxygenase, NSAIDs, Prevention, Prostaglandins",
author = "Marnett, {Lawrence J.} and DuBois, {Raymond N.}",
year = "2002",
doi = "10.1146/annurev.pharmtox.42.082301.164620",
language = "English (US)",
volume = "42",
pages = "55--80",
journal = "Annual Review of Pharmacology and Toxicology",
issn = "0362-1642",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - COX-2

T2 - A target for colon cancer prevention

AU - Marnett, Lawrence J.

AU - DuBois, Raymond N.

PY - 2002

Y1 - 2002

N2 - Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention.

AB - Disease prevention is one area that both public and governmental agencies strongly support owing to its potential for an improved lifestyle and a reduction in health care costs. In this review, we focus on the clinical development of one target for cancer prevention, the COX-2 enzyme. This provides an excellent example of how basic research in biochemistry and pharmacology can lead to translational studies and eventually to approval of a drug by the FDA for use as a chemopreventive agent in humans. It is hoped that, as the genome sequence is understood more clearly, other targets will emerge that will provide even more effective drugs for future cancer prevention.

KW - Cancer

KW - Cyclooxygenase

KW - NSAIDs

KW - Prevention

KW - Prostaglandins

UR - http://www.scopus.com/inward/record.url?scp=0036169389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036169389&partnerID=8YFLogxK

U2 - 10.1146/annurev.pharmtox.42.082301.164620

DO - 10.1146/annurev.pharmtox.42.082301.164620

M3 - Article

C2 - 11807164

AN - SCOPUS:0036169389

VL - 42

SP - 55

EP - 80

JO - Annual Review of Pharmacology and Toxicology

JF - Annual Review of Pharmacology and Toxicology

SN - 0362-1642

ER -